Date: 2016-06-07
Type of information: Production agreement
Compound: Xbrane (biosimilar ranibizumab ) biosimilar version of Lucentis®
Company: Xbrane Biopharma (Sweden) Biotechpharma (Sweden)
Therapeutic area: Ophtalmological diseases
Type agreement: production manufacturing
Action mechanism: monoclonal antibody/biosimilar. Ranibizumab is a VEGF inhibitor specifically designed for use in the eye to bind to and inhibit VEGF-A, a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels.
Disease:
Details: * On June 7, 2016, Xbrane Biopharma has entered into an agreement with Biotechpharma UAB regarding scale-up of the production of Xlucane, Xbrane's Ranibizumab biosimilar, in GMP approved facility, further process optimization, the required biochemical characterization and development of the CMC documentation.
Financial terms:
Latest news:
